|
Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, Marín F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab. 2009 Jul;10(6):632-42. PubMed PMID: 19799531.
AÑO: 2009; IF: 3.989
|
19799531
|
Hernández-Romero D, Marín F, Lee KW, Roldán V, Caturla J, Corral J, Valdés M, Lip GY, Vicente V, González-Conejero R. Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. Thromb Haemost. 2010 Sep;104(3):650-2. doi: 10.1160/TH10-01-0022. Epub 2010 Jun 29. PubMed PMID: 20589311.
AÑO: 2010; IF: 4.701
|
|
Hernández-Romero D, Ruiz-Nodar JM, Marín F, Tello-Montoliu A, Roldán V, Mainar L, Pérez-Andreu V, Antón AI, Bonaque JC, Valdés M, Vicente V, González-Conejero R. CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. Ann Med. 2010 Sep;42(6):439-46. doi: 10.3109/07853890.2010.499131. PubMed PMID: 20673165.
AÑO: 2010; IF: 4.323
|
|
López-Cuenca A, Marín F, Roldán V, González-Conejero R, Hernández-Romero D, Valdés M, Lip GY. Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Ann Med. 2010 Dec;42(8):562-75. doi: 10.3109/07853890.2010.507601. Epub 2010 Aug 4. Review. PubMed PMID: 20681943.
AÑO: 2010; IF: 4.323
|
|
Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14. PubMed PMID: 21497043.
AÑO: 2011; IF: 14.156
|